Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
DRMA 
Dermata Therapeutics Inc (DRMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/30/2025: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.96% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.34M USD | Price to earnings Ratio 0.15 | 1Y Target Price 10 |
Price to earnings Ratio 0.15 | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 0.53 | 52 Weeks Range 1.58 - 16.50 | Updated Date 12/31/2025 |
52 Weeks Range 1.58 - 16.50 | Updated Date 12/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 15.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -96.46% | Return on Equity (TTM) -203.36% |
Valuation
Trailing PE 0.15 | Forward PE - | Enterprise Value -2323806 | Price to Sales(TTM) - |
Enterprise Value -2323806 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 1026457 | Shares Floating 828926 |
Shares Outstanding 1026457 | Shares Floating 828926 | ||
Percent Insiders 11.29 | Percent Institutions 8.98 |
Upturn AI SWOT
Dermata Therapeutics Inc
Company Overview
History and Background
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel treatments for dermatological conditions. Founded in 2015, the company has progressed through preclinical and early clinical stages with its lead drug candidates.
Core Business Areas
- Dermatological Therapeutics Development: Dermata focuses on developing small molecule drugs targeting inflammatory and infectious skin diseases. Their primary research and development efforts are concentrated on conditions such as atopic dermatitis and psoriasis.
Leadership and Structure
Dermata Therapeutics Inc. is led by a management team with expertise in drug development and the pharmaceutical industry. The company operates with a lean structure, typical of clinical-stage biotechs, focusing on R&D and clinical trials.
Top Products and Market Share
Key Offerings
- DRM04 (currently in development): DRM04 is an investigational topical small molecule inhibitor of Janus kinase (JAK) signaling, intended for the treatment of atopic dermatitis. As a clinical-stage asset, there is no current market share or revenue. Competitors in the atopic dermatitis space include Sanofi (Dupixent), AbbVie (Skyrizi), and Pfizer (Xeljanz Topical).
- DRM01 (currently in development): DRM01 is an investigational topical small molecule inhibitor of diacylglycerol O-acyltransferase 1 (DGAT1), intended for the treatment of acne vulgaris. As a clinical-stage asset, there is no current market share or revenue. Competitors in the acne vulgaris market include Galderma (Differin) and Johnson & Johnson (Tretinoin).
Market Dynamics
Industry Overview
The dermatology market is substantial and growing, driven by increasing prevalence of chronic skin conditions, aging populations, and demand for improved treatment options. The market encompasses both prescription and over-the-counter products.
Positioning
Dermata Therapeutics Inc. aims to position itself as a developer of innovative topical therapies for unmet needs in dermatology. Its competitive advantage lies in its differentiated drug candidates targeting specific inflammatory pathways.
Total Addressable Market (TAM)
The global market for atopic dermatitis treatments is projected to reach tens of billions of dollars, and the acne treatment market is also a multi-billion dollar industry. Dermata is positioned to address segments of these markets with its pipeline drugs.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with distinct mechanisms of action.
- Experienced management team with drug development expertise.
- Focus on significant unmet needs in dermatology.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful clinical trials and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Growing demand for effective and safe dermatological treatments.
- Potential for strategic partnerships or acquisitions by larger pharma companies.
- Expansion into other dermatological indications.
Threats
- Failure to demonstrate efficacy or safety in clinical trials.
- Competition from established and emerging therapies.
- Regulatory hurdles and lengthy approval processes.
- Financing risks associated with clinical development.
Competitors and Market Share
Key Competitors
- Sanofi (SNY)
- AbbVie Inc. (ABBV)
- Pfizer Inc. (PFE)
- Galderma Pharma SA (Private)
- Johnson & Johnson (JNJ)
Competitive Landscape
Dermata Therapeutics Inc. faces competition from established pharmaceutical companies with broad portfolios and significant R&D budgets. Its advantage lies in potentially developing novel therapies that address specific patient needs not fully met by existing treatments. However, it is at a significant disadvantage in terms of market presence and financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by progress in preclinical research and advancement into early-stage clinical trials for its lead assets.
Future Projections: Future growth projections are contingent on the successful completion of clinical trials, regulatory approvals, and potential commercialization of its drug candidates.
Recent Initiatives: Recent initiatives likely involve progressing its drug candidates through clinical development phases, including initiating and conducting Phase 1 and Phase 2 trials.
Summary
Dermata Therapeutics Inc. is a promising clinical-stage biotechnology company with novel drug candidates for dermatological conditions like atopic dermatitis and acne. Its strengths lie in its focused pipeline and experienced team. However, as a pre-revenue company, it faces significant risks related to clinical trial success, regulatory approval, and substantial competition from larger, established pharmaceutical players. Careful management of its cash burn and successful execution of its clinical development strategy are crucial for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry market research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.